ライフサイエンスコーパス: in vivo gene therapy

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 a clinically relevant preclinical model for in vivo gene therapy.

2 ted viruses (AAVs) have been used widely for in vivo gene therapy.

3 in vitro or ex vivo as well as for localized in vivo gene therapy.

4 s especially for the use of retroviruses for in vivo gene therapy.

5 s especially for the use of retroviruses for in vivo gene therapy.

6 lentiviral vectors are a promising tool for in vivo gene therapy.

7 er half-lives, resulting in more-efficacious in vivo gene therapy.

8 totic genes appears promising for successful in vivo gene therapy.

9 notypic correction of murine hemophilia A by in vivo gene therapy.

10 requently applied gene transfer vehicles for in vivo gene therapy.

11 s administration of viral vectors, so-called in vivo gene therapy.

12 ranging from ex vivo stem cell generation to in vivo gene therapy.

13 he potential of AAV-2 vectors in ex vivo and in vivo gene therapy and may form the basis for developi

14 may be a possible target cell population for in vivo gene therapy applications, including the sustain

15 ors may be very useful both for in vitro and in vivo gene therapy applications.

16 Virus vectors for human in vivo gene therapy based on the viruses mentioned abov

17 For many in vivo gene therapy clinical applications, it is desira

18 nanocomplexes have widespread potential for in vivo gene therapy due to their targeted transfection

19 report also demonstrates the feasibility of in vivo gene therapy for LGMD patients by using AAV vect

20 timate goal of developing safe and effective in vivo gene therapy for the treatment of Canavan diseas

21 ecombinant E1-deleted adenoviral vectors for in vivo gene therapy has been limited by the attendant i

22 monogenic hyperlipidemia in mouse models by in vivo gene therapy has been short-lived and associated

23 s become a popular and successful vector for in vivo gene therapy; however, its biology has yet to be

24 urosis have provided evidence for successful in-vivo gene therapy in humans.

25 dvanced Parkinson's disease, suggesting that in-vivo gene therapy in the adult brain might be safe fo

26 for the development of effective ex vivo and in vivo gene therapy modalities to counter the highly me

27 hese data provide the first demonstration of in vivo gene therapy of hemophilia A.

28 Finally, in vivo gene therapy of liver-expressed genes by chimeri

29 ns in the liver, one of the main targets for in vivo gene therapy, raise important concerns.

30 tic inflammatory events and may allow for an in vivo gene therapy strategy to prevent insulitis and t

31 Thus, to improve the activity of exendin-4 in vivo, gene therapy system was developed as an alterna

32 For in vivo gene therapy, these novel RDTR/SCF-displaying LV

33 udy, we evaluated the safety and efficacy of in vivo gene therapy using a foamy virus vector for the

34 prove to be a useful model for investigating in vivo gene therapy using human stem/precursor cells.

35 se of herpes simplex virus (HSV) vectors for in vivo gene therapy will require the targeting of vecto

WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。